ClinicalTrials.gg
Enrolling by invitationNCT07437768Updated Feb 27, 2026

Vonoprazan Test for PPI Refractory GERD

An interventional study of Patients received a 4-week treatment of vonoprazan 20 mg once daily (VOCINTI®) in Refractory GERD, NERD and PCAB, sponsored by Fu Jen Catholic University Hospital. Enrolling by invitation at 1 site in Taiwan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Fu Jen Catholic University Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing vonoprazan in Gastroesophageal Reflux — 5 open to participants now, 5 under way, 1 of them phase 3. vonoprazan · Gastroesophageal Reflux.

Planned enrollment
9th of 16
100 · median 118
Started
2025
with 3 others
No phase
5 of 16
3 open now
Registered
14th of 16
by date
Lead sponsor
1 of 16
Fu Jen Catholic University Hospital

Among the 16 studies testing vonoprazan in Gastroesophageal Reflux, this one is the 9th largest by planned enrollment, is one of 4 that started in 2025, is one of 5 with no phase, and was the 14th registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

5 of the 16 studies testing vonoprazan in Gastroesophageal Reflux are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vonoprazan

vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing vonoprazan in Gastroesophageal Reflux, or all of them as a file.
02

Study summary

Among patients suffering from gastroesophageal reflux disease (GERD) symptoms, esophageal pH monitoring and the assessment of symptom-reflux correlation can identify two distinct subgroups characterized by normal acid exposure: functional heartburn and reflux hypersensitivity. Given the absence of abnormal acid exposure in these groups, conventional antacid therapies often yield unsatisfactory clinical outcomes.

Therefore, in cases of PPI-refractory GERD, it is hypothesized that patients with underlying abnormal acid reflux will respond to Vonoprazan, a more potent potassium-competitive acid blocker (P-CAB). Conversely, those whose symptoms are unrelated to acid reflux are expected to show poor response. For future refractory patients without definitive endoscopic evidence of GERD (such as Los Angeles Grade B, C, or D esophagitis, peptic stricture, or histologically confirmed Barrett's esophagus), a Vonoprazan therapeutic trial could potentially bypass the need for invasive high-resolution manometry (HRM) and 24-hour pH-impedance monitoring. Evaluating the efficacy of Vonoprazan may offer diagnostic insights while minimizing patient discomfort and reducing overall healthcare expenditures.

03

Conditions studied

  • Refractory GERD
  • NERD
  • PCAB
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 20 and 75 years.
  • Outpatients at Fu Jen Catholic University Hospital who had undergone esophagogastroduodenoscopy (EGD) within the past year.
  • Presence of persistent GERD symptoms, including acid regurgitation, heartburn, chest pain, globus sensation, or chronic cough. PPI- GERD, defined as persistent symptoms despite receiving at least 8 weeks of standard-dose proton pump inhibitor (PPI) therapy (GerdQ > = 8).
  • Scheduled to undergo high-resolution manometry (HRM) and 24-hour esophageal pH-impedance monitoring.
  • Patients with a history of any grade of erosive esophagitis confirmed by gastroscopy.

Exclusion criteria

Exclusion Criteria:

  • major esophageal motility disorders
  • history of upper gastrointestinal surgery
  • malignant tumors
  • liver cirrhosis.
  • esophageal strictures
  • esophageal varices
  • gastrointestinal obstruction
  • significant acute GI bleeding
  • LA Grade B, C, or D erosive esophagitis,
  • esophageal peptic stricture
  • -proven Barrett's esophagus
  • severe renal impairment ( \< 30 mL/min)
  • long-term dialysis, pregnancy
  • to vonoprazan or its .
  • patients currently taking atazanavir sulfate or rilpivirine hydrochloride,
  • dependent on tube feeding
  • unable to cooperate due to impaired consciousness
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    single arm. All patient received Vonoprazan

    Patients scheduled for high-resolution manometry (HRM) and 24-hour esophageal pH-impedance monitoring due to GERD symptoms were invited to participate in this study. Following the attainment of informed consent, participants completed a series of GERD-related questionnaires on the day of their examination. Subsequently, they were prescribed a 4-week course of VOCINTI®, a potassium-competitive acid blocker (P-CAB), at a daily oral dose of vonoprazan 20 mg. At the 4-week follow-up visit, the clinical reports for HRM and 24-hour pH-impedance monitoring were reviewed. During this visit, patients completed the GERD-related questionnaires for a second time. Subsequent therapeutic management was then determined based on the comprehensive diagnostic results.

    Drug: Patients received a 4-week treatment of vonoprazan 20 mg once daily (VOCINTI®)

Interventions

  • DrugVonoprazanStudies of VonoprazanVonoprazan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants undergoing HRM and 24-hour pH-impedance monitoring were enrolled after providing informed consent. Baseline GERD-related questionnaires were administered on the day of the procedure. Patients then received a 4-week treatment of vonoprazan 20 mg once daily (VOCINTI®). After four weeks, patients returned for a follow-up visit to review their diagnostic reports and complete a second set of questionnaires. Final treatment strategies were adjusted according to the test findings.

06

What researchers measure

Primary outcomes

  1. All participants were evaluated using the following validated symptom questionnaires: The GERD Questionnaire

    The GERD Questionnaire (GerdQ) includes 4 positive predictors (heartburn, regurgitation, reflux-related sleep disturbance, and use of over-the-counter medications) and 2 negative predictors (epigastric pain and nausea) for GERD. The GerdQ score ranges from 0 to 18. A higher score indicates a higher probability of GERD and a greater symptom burden. A cutoff score of 8 or higher is generally used to identify patients with a high likelihood of having GERD.

    Time frame: 4 weeks

Secondary outcomes

  1. The Reflux Symptom Index (RSI)

    The Reflux Symptom Index (RSI) consists of 9 items (e.g., hoarseness, frequent throat clearing, and globus sensation), each rated on a scale from 0 (no problem) to 5 (severe) based on the severity of symptoms. Minimum score: 0 Maximum score: 45

    Time frame: 4 weeks

  2. The 5-item Brief Symptom Rating Scale (BSRS-5)

    The BSRS-5 score ranges from 0 to 20. A higher score indicates greater psychological distress. The 5-item Brief Symptom Rating Scale (BSRS-5) was used to screen for common psychiatric conditions, such as anxiety and depression; a score ≥ 6 indicates potential psychological morbidity.

    Time frame: 4 weeks

  3. The Pittsburgh Sleep Quality Index (PSQI)

    The Pittsburgh Sleep Quality Index (PSQI) is a 7-item self-rated questionnaire used to assess sleep quality over the preceding month; a global PSQI score \> 5 indicates poor sleep quality or sleep disturbance. The PSQI global score ranges from 0 to 21. A higher score indicates poorer sleep quality.

    Time frame: 4 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Feb 2026, 1 month.

Of 194 non-industry interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 68. This study's 1 month is below that.

Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 27, 2026
StartActual
Dec 24, 2025
Primary completionActual
Feb 9, 2026
CompletionEst.
Oct 28, 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07437768
Lead sponsor
Fu Jen Catholic University Hospital
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Dec 24, 2025
Primary completion
Feb 9, 2026
Completion
Oct 28, 2026 (estimated)
Last update
Feb 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion